Sakar Healthcare
SAKARNSE

Sakar Healthcare

₹515.30-0.35 (0.07%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
492.20
Today’s high
519.15
52 week low
214.30
52 week high
577.95
Open price
515.00
Previous close
515.65
Live volume
51,371
Lower circuit
412.25
Upper circuit
618.35

Fundamentals

Market Cap
₹1,147Cr
ROE
6.43%
P/E Ratio(TTM)
45.47
EPS(TTM)
11.34
P/B Ratio
3.78
Dividend Yield
0.00%
Industry P/E
31.44
Book Value
136.29
Debt to Equity
0.24
Face Value
10

Financials

*All values are in Rs. Cr
No Graph Data To Display
Quarterly
Yearly

About

Sakar Healthcare is a prominent player within India's pharmaceutical industry, distinguished by its vertically integrated manufacturing capabilities, particularly in the field of oncology. The company's vision is to become a global healthcare organization built on the three pillars of people, partnership, and performance to deliver world-class healthcare solutions. Its mission focuses on strengthening core competencies to be the preferred choice for partnerships and exploring new market opportunities to expand its product range. The company operates state-of-the-art facilities to produce both Active Pharmaceutical Ingredients (APIs) and finished formulations, ensuring quality control across the value chain. Its four manufacturing plants create a wide range of dosage forms, which include oral liquids, solids, injectables, and dry powder inhalers. With a strong export focus supported by a global distribution network, the company successfully serves customers in over 60 countries around the world.;
MD/CEO
Mr. Sanjay S. Shah
Founded in
2004
NSE symbol
SAKAR
Industry

Shareholding Pattern

Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Promoters
52.86%
Retail And Others
35.78%
Other Domestic Institutions
11.36%

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
Innova CaptabINNOVACAP
₹704.40
+0.45 (0.06%)
L
    H
    4,026.3530.413.94
    ₹388.25
    -4.50 (1.15%)
    L
      H
      3,666.0140.95.03
      Aarti DrugsAARTIDRUGS
      ₹352.70
      +6.30 (1.82%)
      L
        H
        3,169.8115.662.16
        ₹288.60
        -0.10 (0.03%)
        L
          H
          2,912.2058.24.61
          Livesquawk
          Sarkar Healthcare's Q3 revenue surged to 703M INR, up from 434M YoY. This marks a strong performance in the healthcare sector.
          Livesquawk
          Sakar Healthcare's Q3 EBITDA rose to 186M INR from 118M INR YoY. EBITDA margin slightly declined to 26.4% from 27.1% YoY.
          Livesquawk
          Sakar Healthcare's unit, Accord Healthcare, gets EU approval for Imatinib 100 MG & 400 MG. This approval allows Sakar Healthcare to supply to Europe, likely boosting sales.
          Livesquawk
          Sakar Healthcare gains nine new marketing authorizations, totaling eleven for cancer products in Europe and emerging markets. Authorized products include key cancer treatments: Carboplatin, Docetaxel, and Tamoxifen.
          2026
          5
          Feb
          Quarterly Result
          Release date
          2025
          7
          Nov
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks